Pancreatic Cancer Research

ResearcherTel Aviv UniversityActive in the last 2 years

Guy Lahat

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5001549786. Sources: OpenAlex.

Their work

Papers
14 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 3 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 14

  1. Intraoperative Management Strategies for Unresectable Pancreatic Adenocarcinoma: A Propensity-Weighted Cohort Study. Last author DOI 10.1177/00031348261499335↗
  2. Lymph node-targeted Nanovaccine Reshapes the Tumor Microenvironment to Suppress PDAC Progression and Metastasis Co-author DOI 10.21203/rs.3.rs-9958073/v1↗
  3. Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option? Co-author DOI 10.3390/cancers15113049↗
  4. Prognostic significance of pancreatic fistula and postoperative complications after pancreaticoduodenectomy in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.surge.2019.07.003↗
  5. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08469-8↗
  6. Protective Desmoplasia in Pancreatic Adenocarcinoma: High Vitamin D Receptor Expression and Collagen Content. Co-author DOI 10.21873/anticanres.14667↗
  7. Desmoplasia in Lymph Node Metastasis of Pancreatic Adenocarcinoma Reveals Activation of Cancer-Associated Fibroblasts Pattern and T-helper 2 Immune Cell Infilt… Co-author DOI 10.1097/mpa.0000000000001261↗
  8. MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis. Last author DOI 10.18632/oncotarget.26804↗
  9. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. First author DOI 10.1016/j.ejso.2018.07.057↗
  10. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival. Co-author DOI 10.1245/s10434-017-6237-0↗
  11. ASO Author Reflections: Even in Pancreatic Cancer, not all N Diseases are Created Equal. First author DOI 10.1245/s10434-018-6813-y↗
  12. Unique cellular interactions between pancreatic cancer cells and the omentum. Last author DOI 10.1371/journal.pone.0179862↗
  13. Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology… Co-author DOI 10.1186/s12957-016-0983-5↗
  14. Pancreatic cancer: surgery is a feasible therapeutic option for elderly patients. Co-author DOI 10.1186/1477-7819-9-10↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joseph M. Klausner · 11 shared papers, 2016–2023 · strength 1.13
  2. Nir Lubezky · 9 shared papers, 2011–2026 · strength 1.08
  3. Ido Wolf · 7 shared papers, 2016–2023 · strength 0.70
  4. Lior Orbach · 2 shared papers, 2026 · strength 0.60
  5. Eran Nizri‏ · 6 shared papers, 2016–2020 · strength 0.59
  6. Ido Nachmany · 5 shared papers, 2011–2020 · strength 0.36
  7. Alex Barenboim · 3 shared papers, 2018–2023 · strength 0.35
  8. Daniella Vaskovich‐Koubi · 1 shared paper, 2026 · strength 0.24
  9. Helena F. Florindo · 1 shared paper, 2026 · strength 0.24
  10. Ronit Satchi‐Fainaro · 1 shared paper, 2026 · strength 0.24
  11. Dov Hershkovitz · 1 shared paper, 2026 · strength 0.24
  12. Yossi Maman · 1 shared paper, 2023 · strength 0.18
  13. Uri Neeman · 1 shared paper, 2020 · strength 0.11
  14. Adi Vaknine Bahat · 1 shared paper, 2020 · strength 0.11
  15. Moran Lemberger · 1 shared paper, 2019 · strength 0.10
  16. Talia Golan · 1 shared paper, 2020 · strength 0.10
  17. Valerya Feygenzon · 1 shared paper, 2017 · strength 0.08
  18. Josef M. Klausner · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.